The authors present data from an open trial of fluvoxamine (median daily dosage: 200 mg) in the treatment of generalized anxiety disorder, panic disorder, and obsessive-compulsive disorder in 19 older outpatients (mean age = 66.8). Of the 12 subjects completing the 21-week trial, 8 achieved a good response (50% reduction in symptom measures) and 7 were rated as much or very much improved. Fluvoxamine pharmacotherapy also had a significant effect in reducing comorbid depressive symptoms and in increasing levels of functioning. These data support the effectiveness of fluvoxamine in older subjects with anxiety disorders (particularly generalized anxiety disorder) and warrant further double-blind, placebo-controlled evaluation. (J Geriatr Psychiatry Neurol 2000; 13:43—48).
Get full access to this article
View all access options for this article.
References
1.
Blazer D.The epidemiology of anxiety disorders: an age comparison. In: Salzman C, Lebowitz B, eds. Anxiety in the elderly. New York: Springer, 1991:17-30.
2.
Blazer DG.Generalized anxiety disorder and panic disorder in the elderly: a review. Harv Rev Psychiatry1997; 5:18-27.
3.
Schweizer E. Generalized anxiety disorder: longitudinal course and pharmacologic treatment. In: Pollack MH, Otto MW, eds. Anxiety disorders, longitudinal course and treatment. Philadelphia : WB Saunders, 1995:843-857.
4.
First M, Spitzer RL, Gibbon M, Williams JBW.Structured Clinical Interview for DSM-IV Axis I Disorders-Patient Edition (SCID-I/P). Version 2.0 ed. New York: New York State Psychiatric Institute, 1995.
Hamilton M.The assessment of anxiety states by rating. Br J Med Psychol1959; 32:50-55.
7.
Brown TA, Antony MM, Barlow DH.Psychometric properties of the Penn State Worry Questionnaire in a clinical anxiety disorders sample. Behav Res Ther1992; 30:33-37.
8.
Shear MK, Brown TA, Barlow DH, et al. Multicenter collaborative panic disorder severity scale. Am J Psychiatry1997; 154:1571-1575.
9.
Goodman WK, Price LH, Rasmussen SA, et al. The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability . Arch Gen Psychiatry1989; 46:1006-1011.
10.
Folstein MF, Folstein SW, McHugh PR. Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res1975; 12:189-198.
11.
Endicott J, Spitzer RL, Fleiss JL, Cohen JL.The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry1976; 33:766-771.
12.
Fillenbaum GG.Multidimensional functional assessment of older adults. The Duke Older Americans Resources and Services Procedures. Hillsdale, NJ: Lawrence Associates, 1988:
13.
McHorney CA, Ware JE Jr, Raczek AE.The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care1993; 31:247-263.
14.
Lingjaerde O, Ahlfors UG, Bech P, et al. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl1987; 334:1-100.
15.
Guy W.ECDEU assessment manual for psychopharmacology. U.S. Department of Health, Education and Welfare publication (ADM) 76-338. Rev. ed. Rockville, MD: National Institute of Mental Health, 1976.
16.
Miller MD, Paradis CF, Houck PR, et al. Rating chronic medical illness burden in geropsychiatric practice and research: application of the Cumulative Illness Rating Scale. Psychiatry Res1992; 41:237-248.
17.
Hamilton M.A rating scale for depression. J Neurol Neurosurg Psychiatry1960; 23:56-62.
Black DW, Wesner R, Bowers W, Gabel J.A comparison of fluvoxamine, cognitive therapy and placebo in the treatment of panic disorder. Arch Gen Psychiatry1993; 50:44-50.
20.
de Beurs E, VanBalkom AJ, Lange A, et al. Treatment of panic disorder with agoraphobia—comparison of fluvoxamine, placebo, and psychological panic management combined with exposure and in-vivo alone. Am J Psychiatry1995; 152:683-691.
21.
Tollefson GD, Rampey AH Jr, Potvin JH, et al. A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder. Arch Gen Psychiatry1994; 51:559-567 [published erratum appears in Arch Gen Psychiatry1994; 51:864].
22.
Jenike MA, Hyman S, Baer L, et al. A controlled trial of fluvoxamine in obsessive-compulsive disorder: implications for a serotonergic theory [see comments]. Am J Psychiatry1990; 147:1209-1215.
23.
Freeman CP, Trimble MR, Deakin JF, et al. Fluvoxamine versus clomipramine in the treatment of obsessive compulsive disorder : a multicenter, randomized, double-blind, parallel group comparison . J Clin Psychiatry1994; 55:301-305.
24.
Hoehn-Saric R, McLeod DR, Zimmerli WD.Differential effects of alprazolam and imipramine in generalized anxiety disorder: somatic versus psychic symptoms. J Clin Psychiatry1988; 49:293-301.
25.
Rickels K, Weisman K, Norstad N, et al. Buspirone and diazepam in anxiety: a controlled study. J Clin Psychiatry1982; 43:81-86.
26.
Ballenger JC, Burrows GD, DuPont RL Jr, et al. Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. I. Efficacy in short-term treatment. Arch Gen Psychiatry1988; 45:413-422.
27.
Tesar GE, Rosenbaum JF, Pollack MH, et al. Clonazepam versus alprazolam in the treatment of panic disorder: interim analysis of data from a prospective, double-blind, placebo-controlled trial. J Clin Psychiatry1987; 48(suppl):16-21.
28.
Hewlett WA, Vinogradov S, Agras WS.Clonazepam treatment of obsessions and compulsions. J Clin Psychiatry1990; 51:158-161.
29.
DeBoer M, Denvelde WO, Falger PJR, et al. Fluvoxamine treatment for chronic PTSD—a pilot-study. Psychother Psychosom1992; 57:158-163.
30.
Lin E, VonKorff M, Katon W, et al. The role of the primary care physician in patients' adherence to antidepressant therapy. Med Care1995; 33:67-74.
